The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Elevated chronic inflammatory factors and myeloid‐derived suppressor cells indicate poor prognosis in advanced melanoma patients
Open accessAbstract
Chronic inflammation is considered to be one of the hallmarks for tumor initiation and progression. Moreover, a long‐term production and accumulation of inflammatory factors lead to a local and systemic immunosuppression associated with cancer progression. However, the correlation between inflammatory mediators, immunosuppressive cells and the clinical outcome of malignant melanoma patients was poorly investigated. In this study, we performed a complex analysis of various inflammatory factors, myeloid‐derived suppressor cells (MDSCs) and regulatory T cells (Tregs) in the peripheral blood of patients suffering from malignant melanoma of different stages. We demonstrated that levels of serum IL‐1β, IFN‐γ and CXCL10 were significantly increased in advanced melanoma patients. In addition, these factors were found to be associated with an increased frequency of MDSCs and Tregs as compared to age‐ and gender‐matched healthy donors. Importantly, advanced melanoma patients with signs of progression displayed markedly elevated concentrations of IL‐1β and CXCL10 as compared to patients with stable disease. Moreover, an enrichment of circulating monocytic (Mo)‐MDSCs significantly correlated with a decreased progression free survival of these patients. Our data highlight a complex association between circulating inflammatory mediators, Mo‐MDSCs and the clinical outcome as well as suggest that their levels in patients with advanced melanoma are of important prognostic value allowing the identification of those with high risk of disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Immunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Tanchot, C., Terme, M., Pere, H., Tran, T., Benhamouda, N., Strioga, M., Banissi, C., Galluzzi, L., Kroemer, G., & Tartour, E. (2013) · Cancer Microenvironment · doi:10.1007/s12307-012-0122-y · Cited by 138 · cited 1×
“Tregs and the enhancement of their inhibition of activated tumor-specific CD4(1) and CD8(1) T cells that can occur through different pathways.(9,10,19,20) Multiple reports published during the last decade described a strong correlation between the development of chronic inflammation in the tumor microenvironment and t…”
Background
Cited by
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, X., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,042
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Li, K., Shi, H., Zhang, B., Ou, X., Ma, Q., Chen, Y., Shu, P., Li, D., & Wang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00670-9 · Cited by 988
Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape
Mohme, M., Riethdorf, S., & Pantel, K. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.144 · Cited by 602
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01282-8 · Cited by 591
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Weber, R., Fleming, V., Hu, X., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 538
Self-citationTargeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Interleukin-1 Beta—A Friend or Foe in Malignancies?
Bent, R., Moll, L., Grabbe, S., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082155 · Cited by 444
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Fleming, V., Hu, X., Weber, R., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00398 · Cited by 443
Self-citationThe Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
Umansky, V., Blattner, C., Gebhardt, C., & Utikal, J. (2016) · Vaccines · doi:10.3390/vaccines4040036 · Cited by 438
Self-citationGebhardt, C., Sevko, A., Jiang, H., Lichtenberger, R., Reith, M., Tarnanidis, K., Holland-Letz, T., Umansky, L., Beckhove, P., Sucker, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0676 · Cited by 367
Self-citationTumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
Das, S., Shapiro, B., Vucic, E. A., Vogt, S., & Bar-Sagi, D. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2080 · Cited by 366
IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy
Weber, R., Groth, C., Lasser, S., Arkhypov, I., Petrova, V., Altevogt, P., Utikal, J., & Umansky, V. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104254 · Cited by 309
Self-citationSade-Feldman, M., Kanterman, J., Klieger, Y., Ish-Shalom, E., Olga, M., Saragovi, A., Shtainberg, H., Lotem, M., & Baniyash, M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3104 · Cited by 201
Metadata
- Authors
- Jiang, H., Gebhardt, C., Umansky, L., Beckhove, P., Schulze, T. J., Utikal, J., & Umansky, V.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2014-11-12
- Volume
- 136
- Issue
- 10
- Pages
- 2352-2360
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2133495780
- Cited by
- 169
- References
- 6
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.